Explore

Trendline Trendline
Amylyx Pharmaceuticals to Present Research on Post-Bariatric Hypoglycemia at ENDO 2026

Amylyx Pharmaceuticals to Present Research on Post-Bariatric Hypoglycemia at ENDO 2026

Amylyx Pharmaceuticals to Present Research on Post-Bariatric Hypoglycemia at ENDO 2026
Rapid Read Rapid Read
Dexcom CONNECT Study Shows Significant Benefits of CGM for Type 2 Diabetes Patients

Dexcom CONNECT Study Shows Significant Benefits of CGM for Type 2 Diabetes Patients

DexCom, Inc. has announced the results of the CONNECT randomized controlled trial, which demonstrates significant benefits of using the Dexcom G7 continuous glucose monitoring (CGM) system for people with Type 2 diabetes not using insulin. The study, presented at the 2026 Scientific Sessions of the American Diabetes Association, showed that the use of Dexcom G7 led to a clinically and statistically significant reduction in HbA1c levels and improved glucose control compared to routine care. The trial involved 283 participants across the United States, with results indicating a 1.6% average reduction in HbA1c for those using the Dexcom G7. The study highlights the potential of CGM systems to become a new standard of care for managing Type 2 diabetes.
Trendline Trendline
Abivax Faces Stock Volatility Amid Ulcerative Colitis Drug Trial Results

Abivax Faces Stock Volatility Amid Ulcerative Colitis Drug Trial Results

Abivax Faces Stock Volatility Amid Ulcerative Colitis Drug Trial Results
Trendline Trendline
GSK Acquires US Cancer Treatment Firm Nuvalent for $10.6 Billion to Boost Oncology Portfolio

GSK Acquires US Cancer Treatment Firm Nuvalent for $10.6 Billion to Boost Oncology Portfolio

GSK Acquires US Cancer Treatment Firm Nuvalent for $10.6 Billion to Boost Oncology Portfolio
Trendline Trendline
AI-Driven Approaches Revolutionize Clinical Trial Feasibility and Site Selection

AI-Driven Approaches Revolutionize Clinical Trial Feasibility and Site Selection

AI-Driven Approaches Revolutionize Clinical Trial Feasibility and Site Selection
Rapid Read Rapid Read
Dexcom's CONNECT Study Shows Significant Benefits of CGM for Type 2 Diabetes Patients Not Using Insulin

Dexcom's CONNECT Study Shows Significant Benefits of CGM for Type 2 Diabetes Patients Not Using Insulin

Dexcom, Inc. has announced the results of its CONNECT randomized controlled trial, which demonstrates the significant benefits of using the Dexcom G7 continuous glucose monitoring (CGM) system for individuals with Type 2 diabetes who are not using insulin. The study, presented at the 2026 Scientific Sessions of the American Diabetes Association, showed that participants using the Dexcom G7 experienced a clinically and statistically significant reduction in HbA1c levels and improved glucose control compared to those using traditional self-monitoring methods. The trial involved 283 participants across 22 primary care practices in the United States, with 265 completing the 26-week study. Key outcomes included an average 1.6% reduction in HbA1c levels for those using the Dexcom G7, with significant improvements in time spent within the target glucose range.
Rapid Read Rapid Read
FDA-Approved Osteoboost Device Shows Promise in Reducing Bone Density Loss in Post-Menopausal Women

FDA-Approved Osteoboost Device Shows Promise in Reducing Bone Density Loss in Post-Menopausal Women

The Osteoboost device, a wearable belt approved by the FDA in 2024, is designed to combat bone density loss in post-menopausal women diagnosed with osteopenia. The device delivers targeted vibrations to the spine and hips, mimicking the effects of exercise by stimulating bone-building cells called osteoblasts. A study involving 126 women over 50 showed that those using the device experienced significantly less bone strength loss in the spine over a year compared to a placebo group. Despite these promising results, some scientists have criticized the study's conclusions, arguing that the device's localized treatment may not be sufficient for a systemic condition like osteopenia. The device is available by prescription and costs about $1,000, as it is not covered by insurance.
Trendline Trendline
Kailera Therapeutics Prepares for Global Trials Following Record-Breaking IPO

Kailera Therapeutics Prepares for Global Trials Following Record-Breaking IPO

Kailera Therapeutics Prepares for Global Trials Following Record-Breaking IPO
Rapid Read Rapid Read
Target Recalls Baby Wipes Due to Bacterial Contamination Risking Sepsis and Pneumonia

Target Recalls Baby Wipes Due to Bacterial Contamination Risking Sepsis and Pneumonia

Target has issued a recall for its Up & Up brand baby wipes, both fragrance-free and cucumber-scented, following reports of infections in infants. The United States Food and Drug Administration (FDA) found the wipes contaminated with Burkholderia cepacia and Burkholderia gladioli, bacteria that can cause serious infections, including life-threatening sepsis and pneumonia. These products were sold nationwide in Target stores and online. Consumers have reported product discoloration, skin irritations, and infections. The FDA advises consumers to stop using the wipes immediately and return them to any Target store for a full refund. The recall affects packages of various sizes, and Target is coordinating with the manufacturer, Sapro Temizlik Urunleri, to investigate the issue further.
Trendline Trendline
Dietitian Josie Porter Advocates for Selective Supplement Use Amid Industry Growth

Dietitian Josie Porter Advocates for Selective Supplement Use Amid Industry Growth

Dietitian Josie Porter Advocates for Selective Supplement Use Amid Industry Growth
Rapid Read Rapid Read
Target Recalls Baby Wipes Due to Potential Bacterial Contamination Risking Children's Health

Target Recalls Baby Wipes Due to Potential Bacterial Contamination Risking Children's Health

Target has announced a voluntary recall of its Up & Up brand baby wipes due to potential microbial contamination. The recall affects both the Fragrance Free and Fresh Cucumber Scented wipes, sold in various package sizes across Target stores in the U.S. and online. The decision follows consumer complaints and adverse event reports of product discoloration and symptoms such as skin and eye irritation. Testing by the FDA revealed the presence of Burkholderia cepacia complex and Burkholderia gladioli bacteria, which can cause illness, particularly in newborns, infants, and young children with immature immune systems. Target, in collaboration with the manufacturer Sapro Temizlik Urunleri, is advising customers to stop using the affected products immediately and return them for a full refund.
Rapid Read Rapid Read
University of New Mexico Study Reveals Machine Learning Detects Hidden Self-Harm Histories in Veterans

University of New Mexico Study Reveals Machine Learning Detects Hidden Self-Harm Histories in Veterans

A study led by the University of New Mexico School of Medicine has utilized machine learning to uncover hidden self-harm histories in veterans, significantly surpassing traditional diagnosis codes. The research analyzed electronic health records of over 1.3 million patients from the Veterans Health Administration. The machine learning method identified self-harm in 7.9% of patients, compared to just 1.85% detected through diagnosis codes. This approach, combining machine learning with expert chart review and statistical calibration, highlights a substantial gap in visibility between documented self-harm and what is captured in diagnosis codes. The findings, published in the Journal of Medical Internet Research, suggest that relying solely on diagnosis codes may lead to underestimating the need for mental health services.